Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Status:
Not yet recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i)
medications enhance beneficial properties of epicardial adipose tissue including metabolic
flexibility, insulin sensitivity, decreased cell size and reduced inflammation.